These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19799846)

  • 21. Evaluation of Immune Response to Measles Component of MMR Vaccine in Children with HIV Infection Receiving Antiretroviral Therapy.
    Seth A; Deepa S; Dutta R; Chandra J
    Pediatr Infect Dis J; 2016 Jan; 35(1):e8-11. PubMed ID: 26418241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High need for MMR vaccination in HIV infected adults in Austria.
    Grabmeier-Pfistershammer K; Poeppl W; Herkner H; Touzeau-Roemer V; Huschka E; Rieger A; Burgmann H
    Vaccine; 2014 Oct; 32(45):6020-3. PubMed ID: 25203449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route.
    Díaz-Ortega JL; Bennett JV; Castañeda D; Martinez D; de Castro JF
    Vaccine; 2010 Oct; 28(44):7228-32. PubMed ID: 20800111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.
    Kelly HA; Gidding HF; Karapanagiotidis T; Leydon JA; Riddell MA
    BMC Public Health; 2007 Jun; 7():99. PubMed ID: 17555601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
    Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
    Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measles immunization in HIV-infected children. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS.
    Pediatrics; 1999 May; 103(5 Pt 1):1057-60. PubMed ID: 10224192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine.
    Wong-Chew RM; Beeler JA; Audet S; Santos JI
    J Med Virol; 2003 Jun; 70(2):276-80. PubMed ID: 12696117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
    Weinberg A; Gona P; Nachman SA; Defechereux P; Yogev R; Hughes W; Wara D; Spector SA; Read J; Elgie C; Cooper M; Dankner W;
    J Infect Dis; 2006 Jan; 193(2):302-11. PubMed ID: 16362896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children.
    Wong-Chew RM; Islas-Romero R; García-García Mde L; Beeler JA; Audet S; Santos-Preciado JI; Gans H; Lew-Yasukawa L; Maldonado YA; Arvin AM; Valdespino-Gómez JL
    Vaccine; 2006 Jan; 24(5):683-90. PubMed ID: 16154241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Siriaksorn S; Sirisanthana T; Sirisanthana V
    HIV Med; 2006 Oct; 7(7):467-70. PubMed ID: 16925733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.